Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Over 8.7 years of follow up (78% of original HOPE-3 cohort), there was 21% reduction in major adverse cardiovascular event (MACE)-1 and 21% reduction in MACE-2 (MACE-1 + cardiac arrest, heart failure, or coronary revascularisation) with rosuvastatin vs placebo.

Source:

European Heart Journal